Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 1077 with Last Name = 'takahashi' and Initial = 'y'
TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322074(1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.340nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322074(1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.340nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322125(1-(5-[(2,5-difluorobenzyl)oxy]-1-{[1-(trifluoro-me...)
Affinity DataKi:  0.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322125(1-(5-[(2,5-difluorobenzyl)oxy]-1-{[1-(trifluoro-me...)
Affinity DataKi:  0.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322090(US10183913, Example 242 | US11312688, Example 242 ...)
Affinity DataKi:  0.520nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322090(US10183913, Example 242 | US11312688, Example 242 ...)
Affinity DataKi:  0.520nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322118(US10183913, Example 400)
Affinity DataKi:  0.540nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550841(US11312688, Example 400)
Affinity DataKi:  0.540nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322097(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3-methylbutyl)-1...)
Affinity DataKi:  0.590nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322097(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3-methylbutyl)-1...)
Affinity DataKi:  0.590nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550845(1-(2-{5-[(5-Chloro-2-fluorobenzyl)oxy]-3-[(methyla...)
Affinity DataKi:  0.600nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322122(1-(2-{5-[(5-Chloro-2-fluorobenzyl)oxy]-3-[(methyla...)
Affinity DataKi:  0.600nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322094(1-{5-[(2,5-difluorobenzyl)oxy]-1-(2,2-dimethylprop...)
Affinity DataKi:  0.660nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322094(1-{5-[(2,5-difluorobenzyl)oxy]-1-(2,2-dimethylprop...)
Affinity DataKi:  0.660nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322096(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbuty...)
Affinity DataKi:  0.690nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322096(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbuty...)
Affinity DataKi:  0.690nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322083(1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)ox...)
Affinity DataKi:  0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322083(1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)ox...)
Affinity DataKi:  0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322079(US10183913, Example 124 | US11312688, Example 124 ...)
Affinity DataKi:  0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322079(US10183913, Example 124 | US11312688, Example 124 ...)
Affinity DataKi:  0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322132(1-{5-[(2,5-Difluorobenzyl)oxy]-1-(3-fluoro-3-methy...)
Affinity DataKi:  0.850nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322132(1-{5-[(2,5-Difluorobenzyl)oxy]-1-(3-fluoro-3-methy...)
Affinity DataKi:  0.850nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322103(1-[5-(Benzyloxy)-1-(1-cyclopentylethyl)-1H-pyrazol...)
Affinity DataKi:  0.860nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322103(1-[5-(Benzyloxy)-1-(1-cyclopentylethyl)-1H-pyrazol...)
Affinity DataKi:  0.860nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322086(1-[5-(Benzyloxy)-1-(2-cyclopentylethyl)-1H-pyrazol...)
Affinity DataKi:  0.910nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322086(1-[5-(Benzyloxy)-1-(2-cyclopentylethyl)-1H-pyrazol...)
Affinity DataKi:  0.910nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322073(1-{1-(cyclohexylmethyl)-5-[(4-fluoro-2-methylbenzy...)
Affinity DataKi:  0.920nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322073(1-{1-(cyclohexylmethyl)-5-[(4-fluoro-2-methylbenzy...)
Affinity DataKi:  0.920nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(1-[5-(Benzyloxy)-1-(1-cyclohexyl-2-fluoroethyl)-1H...)
Affinity DataKi:  0.960nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(1-[5-(Benzyloxy)-1-(1-cyclohexyl-2-fluoroethyl)-1H...)
Affinity DataKi:  0.960nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550837(1-{1-(Cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.980nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322114(1-{1-(Cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.980nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  0.990nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322120(US10183913, Example 426)
Affinity DataKi:  0.990nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322100(N-Methyl-1-{1-(3-methylbutyl)-5-[(2,4,5-trifluorob...)
Affinity DataKi:  1.10nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322100(N-Methyl-1-{1-(3-methylbutyl)-5-[(2,4,5-trifluorob...)
Affinity DataKi:  1.10nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322107(US10183913, Example 331 | US11312688, Example 331 ...)
Affinity DataKi:  1.30nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322107(US10183913, Example 331 | US11312688, Example 331 ...)
Affinity DataKi:  1.30nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322077(US10183913, Example 115 | US11312688, Example 115 ...)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322092(US10183913, Example 253 | US11312688, Example 253)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322072(1-[5-(benzyloxy)-1-(cyclohexylmethyl)-1H-pyrazol-3...)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322092(US10183913, Example 253 | US11312688, Example 253)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322072(1-[5-(benzyloxy)-1-(cyclohexylmethyl)-1H-pyrazol-3...)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322077(US10183913, Example 115 | US11312688, Example 115 ...)
Affinity DataKi:  1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322093(1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(2-methylpro...)
Affinity DataKi:  1.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322088(1-{5-[(2,5-difluorobenzyl)oxy]-1-(4-fluorobenzyl)-...)
Affinity DataKi:  1.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM550816(US11312688, Example 256)
Affinity DataKi:  1.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322088(1-{5-[(2,5-difluorobenzyl)oxy]-1-(4-fluorobenzyl)-...)
Affinity DataKi:  1.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322099(1-{1-(cyclopentylmethyl)-5-[(2,4,5-trifluorobenzyl...)
Affinity DataKi:  1.90nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322084(1-{5-[(5-chloro-2-fluorobenzyl)oxy]-1-(cyclopentyl...)
Affinity DataKi:  1.90nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

Displayed 1 to 50 (of 1077 total ) | Next | Last >>
Jump to: